Insider buying last 90 days
No open-market insider purchases were filed for NEOG in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every NEOG insider filing, plotted on the chart in Gekko.Open NEOG in Gekko
NASDAQ: NEOG
Neogen (NEOG) Stock Analysis & Forecast
Oct 12 close
$12.00+0.15 (+1.3%)
Gekko Brief
AI summaryOct 12 closeNeogen draws attention this week from Q1 fiscal 2027 results, reported 6 October, where the company posted adjusted earnings of $0.08 per share against a $0.05 estimate, with revenue of $222.8 million, driven by core growth in both the Food and Animal Safety segments. The stock's reaction to that report was a decline of 10.2% despite the beat. CEO Mikheal Nassif purchased 505 shares at $11.95 each on 9 October, for $6,034, adding to an indirect holding now at 1,579 shares. Separately, Neogen was named among key players in the Medical Products industry in a broader sector outlook, and Marketbeat reported a consensus "Hold" rating with an average price target of $12.67.
Neogen closes at $12.00, up 1.3%, sitting between its 50-day average of $12.13 and 200-day average of $10.14, with the stock up 77% over the past year and in the Accumulation zone on the GekkoIndex at a reading of 62.5. Price remains 6.8% below Gekko Fair Value of $12.88.
The next earnings date falls on 14 January 2027, outside the typical 20-trading-day window. Over that horizon, insider buying from the CEO has featured prominently in recent sessions, while no unusual options activity appears in the past 30 days. Seasonality over the next 20 trading days has averaged a 7% return across 5 years, with gains in 4 of them. Analyst coverage from 3 firms shows 2 buy ratings and 1 hold, with a consensus target of $14 implying 16.7% upside.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Neogen price vs fair value
Close $12.00200-day averageGekko Fair Value $12.88
Neogen quick facts
- Market cap
- $2.62B
- P/E ratio
- —
- Forward P/E
- 16
- EPS, TTM
- −$0.26
- Revenue, TTM
- $884.0M
- Profit margin
- -6.3%
- Dividend yield
- —
- Beta
- 1.79
- Volume
- 2.57M avg 5.63M
- 1-year return
- +77.0%
- Typical daily move
- ±6.5%
- Typical 20-day move
- ±9.4%
- 50-day average
- $12.13
- 200-day average
- $10.14
- Next earnings
- Jan 14 before open
- Shares outstanding
- 218.1M
Neogen swing-trade checklist
Neogen scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $12.00 sits between the 50-day ($12.13) and 200-day ($10.14) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
62.5, Accumulation
Reading 62.5 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
6.8% below
Price is 6.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 94 days
Next report Jan 14, 2027, 94 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.0% on average
From this point in the calendar, the next 20 trading days averaged +7% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Neogen stock chart and price history
Neogen closed at $12.00 on Oct 12, 2026, +77.0% over the past year, inside a 52-week range of $5.37 to $14.26.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.9%
- 3 months
- +24.1%
- 6 months
- +31.3%
- 1 year
- +77.0%
The full NEOG chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open NEOG in Gekko
Follow Neogen through every session
Put NEOG on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track NEOG in GekkoFree for 7 days. No credit card required.
About Neogen
Neogen makes and sells products used to check the safety of food and to support animal health. The company is best known for diagnostic test kits that detect contamination risks in food and feed, including tools like its AccuPoint Advanced test, which checks for ATP as a sign of residual living material on surfaces that are meant to be clean.
The business runs through two segments. The Food Safety side offers test kits and related tools that screen for pathogens, spoilage organisms, natural toxins, allergens, genetically modified material, animal by-products, species identification, drug and pesticide residues, and general sanitation problems, serving food and feed producers, grain handlers, processed food makers, meat and dairy businesses, laboratories, and pharmaceutical, cosmetic and veterinary vaccine makers. The Animal Safety side supplies veterinary instruments, medicines, vaccines, parasiticides, diagnostics, pest control and disinfection products, and genomics testing, along with immunoassay kits used to detect drugs in farm and racing animals, residues in meat, and substances in forensic drug screening.
Neogen was founded in 1981 and is based in Lansing, Michigan. Its shares are listed on the NASDAQ under the ticker NEOG.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- neogen.com
Neogen GekkoIndex: the smart money zone
Neogen’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.5, in the Accumulation zone, up 6.4 points over five sessions.
62.5Accumulation
Up 6.4 points over five sessions, from the Neutral zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 64 | −1.6% | −0.1% | ||
| Accumulation (current zone) | 250 | +0.1% | −2.7% | ||
| Neutral | 326 | +0.5% | +3.1% | ||
| Distribution | 39 | −0.4% | +2.4% | ||
| Selling | 3 | Too few readings yet | |||
Average NEOG share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the NEOG price, zone by zone.Track NEOG in Gekko
Is Neogen stock overvalued? Gekko Fair Value
Neogen trades 6.8% below Gekko Fair Value of $12.88, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Neogen shares are worth, recalculated every trading day.
$12.88
Gekko Fair Value, Oct 10, 2026
6.8% Undervalued
At the end of Aug 2026 the price was 6.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open NEOG in Gekko
Neogen insider and Congress trading
No open-market insider purchases were filed for Neogen, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in NEOG were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for NEOG, plotted on the chart in Gekko.Open NEOG in Gekko
Buybacks
Neogen has been buying back its own shares.
- Bought back, year ended May 31, 2019
- $3.14M
- As a share of market cap
- 0.12%
From company filings.
Neogen earnings: next date and track record
Neogen reports on Jan 14, 2027, before the open (94 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Jan 14, 2027
Expected before the open, 94 days away
- EPS estimate
- $0.09
- Revenue estimate
- $227.0M
4 of 8reports beat the EPS estimate
±14%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 6, 2026 AI summary
- What they said
- Neogen's Q1 FY2027 showed solid core revenue growth in both Food and Animal Safety segments, accelerating from Q4 FY2026. Management credited improved commercial execution, stronger operating cadence, and targeted customer engagement. The company is investing in innovation, enterprise systems, and commercial capabilities as part of three strategic priorities: commercial prowess, high-impact innovation, and operational excellence. A strategic collaboration with Hinalea was announced.
- Guidance
- Management expects to build on Q1 momentum to deliver more consistent growth and margin expansion over the long term. FY2027 is characterized as a year of scaling fundamentals, with innovation representing the largest area of investment. Sustainable margin expansion is tied to restoring consistent growth and improving execution.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 6, 2026 | $0.08 est $0.05 | $222.8M est $208.2M | −10.2% |
| Jul 30, 2026 | $0.08 est $0.03 | $225.3M est $212.4M | +28.1% |
| Apr 9, 2026 | $0.09 est $0.05 | $211.2M est $204.5M | −8.9% |
| Jan 8, 2026 | $0.10 est $0.07 | $224.7M est $207.7M | +30.4% |
| Oct 9, 2025 | $0.04 est $0.04 | $209.2M est $203.1M | +3.8% |
| Jul 28, 2025 | −$2.82 est $0.08 | $225.5M est $221.9M | −7.5% |
| Apr 9, 2025 | $0.10 est $0.12 | $221.0M est $224.1M | −20.0% |
| Jan 10, 2025 | $0.11 est $0.11 | $231.3M est $228.3M | −3.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Neogen stock forecast and analyst price targets
Analysts’ average 12-month price target for Neogen is $14.00, +16.7% from the last close, from 3 firms rating the stock in the last 90 days.
$14.00consensus 12-month target, +16.7% from the last close
Each firm’s latest rating in the last 90 days: 3 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 7 | Piper Sandler | $14 | +16.7% |
| Sep 29 | Guggenheim | $14 | +16.7% |
| Sep 28 | William Blair | — | — |
| Sep 15 | Piper Sandler | $14 | +16.7% |
| Aug 26 | Piper Sandler | $14 | +16.7% |
−2.7%average 20-day move after past Accumulation readings
+7.0%average move over the next 20 trading days in the last 5 years
±6.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Neogen seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Neogen averaged +7.0% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.5% | 1 of 5 |
| Next 10 trading days | −3.2% | 2 of 5 |
| Next 15 trading days | +1.4% | 3 of 5 |
| Next 20 trading days | +7.0% | 4 of 5 |
| Next 30 trading days | +6.6% | 4 of 5 |
For scale, NEOG’s typical 20-trading-day move in either direction is about 9.4%.
Neogen market cap and key statistics
Neogen’s market cap is $2.62B and revenue of $884.0M over the last twelve months.
Valuation
- Market cap
- $2.62B
- Forward P/E
- 16
- EPS, TTM
- −$0.26
- Gekko Fair Value
- $12.88
Trading
- Volume
- 2.57M
- Avg volume, 20 days
- 5.63M
- 52-week high
- $14.26
- 52-week low
- $5.37
- Shares outstanding
- 218.1M
Financials
- Revenue, TTM
- $884.0M
- Profit margin
- -6.3%
- Return on equity
- -2.7%
- Quarterly earnings growth, YoY
- −85.6%
Risk and income
- Beta
- 1.79
- Typical daily move
- ±6.5%
- Typical 20-day move
- ±9.4%
Neogen stock news this week
Coverage of Neogen this week reads positive: 11 positive, 3 neutral and 1 negative headlines.
- Zacks Industry Outlook Highlights ICU Medical, Neogen and Trulieve CannabisTradingView, Oct 12
- Neogen CEO Mikheal Nassif buys $6,034 in common stockInvesting.com, Oct 12
- Neogen Corporation (NASDAQ:NEOG) Stock Has Average Price Target of $12.67Defense World, Oct 12
- Neogen CEO Mikheal Nassif buys $6,034 in company stockInvesting.com, Oct 11
- Neogen CEO Mikheal Nassif buys $6,034 in company stock By Investing.comInvesting.com Nigeria, Oct 10
- Neogen CEO Mikheal Nassif buys $6,034 in stock By Investing.comInvesting.com South Africa, Oct 10
Neogen peers
Neogen’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Neogen stock FAQ
What is Neogen’s market cap?
Neogen’s market cap is $2.62B at the Oct 12, 2026 close of $12.00, with 218.1M shares outstanding.
What is the Neogen stock forecast?
The consensus analyst 12-month price target for Neogen is $14.00, +16.7% from the last close. Of the 3 firms that rated the stock in the last 90 days, 2 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Neogen stock overvalued or undervalued?
On Gekko’s estimate Neogen is undervalued: the Oct 12, 2026 close of $12.00 is 6.8% below Gekko Fair Value of $12.88. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Neogen report earnings next?
Neogen is expected to report on Jan 14, 2027, before the market opens (94 days away). Analysts expect earnings of $0.09 per share on revenue of $227.0M. Neogen beat the earnings estimate in 4 of its last 8 reports, moving 14% on average across the report.
What is Neogen’s 52-week high and low?
Neogen’s 52-week high is $14.26 and its 52-week low is $5.37; it closed at $12.00 on Oct 12, 2026, +77.0% over the past year. Over the last five years the shares peaked at $47.80 on Dec 31, 2021.
Is Neogen stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Neogen the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.